Royalty Pharma Appoints Eric Schneider as Chief Technology Officer
September 21 2023 - 8:25AM
Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment
of Eric Schneider as Senior Vice President, Chief Technology
Officer. Eric will also join Royalty Pharma’s Senior Leadership
Committee.
Eric joins Royalty Pharma from Verisk, a global leader in
data-driven analytic insights and solutions, where he was a Senior
Vice President, Chief Data Officer and Chief Technology Officer,
and a member of the Executive Leadership Team. During his tenure at
Verisk, he led their migration to the cloud, mainframe
modernization strategy and Data Governance and Data Strategy Team.
Prior to Verisk, Mr. Schneider held senior IT leadership roles at
Moody’s Investor Services, Barclay’s Capital, AIG and McKinsey
& Company.
“We are thrilled to welcome Eric to Royalty Pharma,” commented
Pablo Legorreta, Royalty Pharma’s founder and Chief Executive
Officer. “Eric brings over 25 years of experience leading strategic
technology initiatives across multiple organizations. Royalty
Pharma will continue to stay on the cutting-edge of technology
innovation, including further advancing our digital and data
capabilities. Eric’s leadership will be incredibly important as we
strengthen our enterprise-wide technology platforms and strategy,
and endeavor to continuously add value to our partners.”
“My time at Verisk leading their Data Strategy, Data Governance
and Data Commercialization initiatives was extremely rewarding,”
said Eric Schneider. “Looking ahead, Royalty Pharma has an enormous
opportunity to fund life sciences innovation and data analytics is
expected to play an increasingly important role in our diligence
and partnering efforts. This is truly an exciting time to join
Royalty Pharma to accelerate their technology initiatives,
especially given their attractive business outlook.”
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of
biopharmaceutical royalties and a leading funder of innovation
across the biopharmaceutical industry, collaborating with
innovators from academic institutions, research hospitals and
non-profits through small and mid-cap biotechnology companies to
leading global pharmaceutical companies. Royalty Pharma has
assembled a portfolio of royalties which entitles it to payments
based directly on the top-line sales of many of the industry’s
leading therapies. Royalty Pharma funds innovation in the
biopharmaceutical industry both directly and indirectly - directly
when it partners with companies to co-fund late-stage clinical
trials and new product launches in exchange for future royalties,
and indirectly when it acquires existing royalties from the
original innovators. Royalty Pharma’s current portfolio includes
royalties on more than 35 commercial products, including Vertex’s
Trikafta, Kalydeco, Orkambi and Symdeko, Biogen’s Tysabri, AbbVie
and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s
Xtandi, GSK’s Trelegy, Novartis’ Promacta, Pfizer’s Nurtec ODT,
Johnson & Johnson’s Tremfya, Roche’s Evrysdi, Gilead’s
Trodelvy, and 11 development-stage product candidates.
Forward-Looking Statements
The information set forth herein does not purport to be complete
or to contain all of the information you may desire. Statements
contained herein are made as of the date of this document unless
stated otherwise, and neither the delivery of this document at any
time, nor any sale of securities, shall under any circumstances
create an implication that the information contained herein is
correct as of any time after such date or that information will be
updated or revised to reflect information that subsequently becomes
available or changes occurring after the date hereof. This document
contains statements that constitute “forward-looking statements” as
that term is defined in the United States Private Securities
Litigation Reform Act of 1995, including statements that express
the company’s opinions, expectations, beliefs, plans, objectives,
assumptions or projections regarding future events or future
results, in contrast with statements that reflect historical facts.
Examples include discussion of Royalty Pharma’s strategies,
financing plans, growth opportunities and market growth. In some
cases, you can identify such forward-looking statements by
terminology such as “may,” “might,” “will,” “should,” “expects,”
“plans,” “anticipates,” “believes,” “estimates,” “target,”
“forecast,” “guidance,” “goal,” “predicts,” “project,” “potential”
or “continue,” the negative of these terms or similar expressions.
Forward-looking statements are based on management’s current
beliefs and assumptions and on information currently available to
the company. However, these forward-looking statements are not a
guarantee of Royalty Pharma’s performance, and you should not place
undue reliance on such statements. Forward-looking statements are
subject to many risks, uncertainties and other variable
circumstances, and other factors. Such risks and uncertainties may
cause the statements to be inaccurate and readers are cautioned not
to place undue reliance on such statements. Many of these risks are
outside of Royalty Pharma’s control and could cause its actual
results to differ materially from those it thought would occur. The
forward-looking statements included in this document are made only
as of the date hereof. Royalty Pharma does not undertake, and
specifically declines, any obligation to update any such statements
or to publicly announce the results of any revisions to any such
statements to reflect future events or developments, except as
required by law. Certain information contained in this document
relates to or is based on studies, publications, surveys and other
data obtained from third-party sources and Royalty Pharma’s own
internal estimates and research. While Royalty Pharma believes
these third-party sources to be reliable as of the date of this
document, it has not independently verified, and makes no
representation as to the adequacy, fairness, accuracy or
completeness of, any information obtained from third-party sources.
In addition, all of the market data included in this document
involves a number of assumptions and limitations, and there can be
no guarantee as to the accuracy or reliability of such assumptions.
Finally, while the company believes its own internal research is
reliable, such research has not been verified by any independent
source. For further information, please reference Royalty Pharma’s
reports and documents filed with the U.S. Securities and Exchange
Commission (“SEC”) by visiting EDGAR on the SEC’s website at
www.sec.gov.
Royalty Pharma Investor Relations and
Communications
+1 (212) 883-6772ir@royaltypharma.com
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Jul 2023 to Jul 2024